VINCERX PHARMA INC (VINC) Stock Price, Forecast & Analysis
NASDAQ:VINC • US92731L3042
VINC Key Statistics, Chart & Performance
The current stock price of VINC is 0.1 USD. In the past month the price decreased by -83.87%. In the past year, price decreased by -99.32%.
VINC Technical Analysis
VINC Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to VINC. The financial health of VINC is average, but there are quite some concerns on its profitability.
VINC Financial Highlights
Over the last trailing twelve months VINC reported a non-GAAP Earnings per Share(EPS) of -20.2. The EPS decreased by -968.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -375.69% | ||
| ROE | -1104.04% | ||
| Debt/Equity | 0 |
VINC Forecast & Estimates
7 analysts have analysed VINC and the average price target is 204 USD. This implies a price increase of 203900% is expected in the next year compared to the current price of 0.1.
VINC Ownership
VINC Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.29 | 390.397B | ||
| AMGN | AMGEN INC | 16.3 | 197.396B | ||
| GILD | GILEAD SCIENCES INC | 17.15 | 193.298B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.84 | 117.026B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.77 | 81.87B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.89 | 42.576B | ||
| INSM | INSMED INC | N/A | 31.656B | ||
| NTRA | NATERA INC | N/A | 29.322B | ||
| BIIB | BIOGEN INC | 12.65 | 28.06B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16 | 20.49B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About VINC
Company Profile
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company which develops antibody drugs. The company is headquartered in Palo Alto, California and currently employs 12 full-time employees. The company went IPO on 2020-03-10. The firm is focused on developing differentiated and novel therapies to address the unmet medical needs of patients with cancer. The company has a next generation bioconjugation platform, called VersAptx. Its product candidates include VIP943 (CD123-KSPi), VIP924 (CXCR5-KSPi), VIP236, and Enitociclib (positive transcription elongation factor beta (P-TEFb)/CDK9 inhibitor). Its VIP943 is developed using its VersAptx platform and combines an anti-CD123 antibody, a novel legumain-cleavable linker and a kinesin spindle protein inhibitor payload enhanced with CellTrapper technology. Enitociclib is a selective CDK9 inhibitor. Enitociclib effectively blocks P-TEFb-mediated activation of RNA polymerase II, preventing transcription of MCL1 and MYC, proteins associated with poor prognosis in various types of cancer.
Company Info
VINCERX PHARMA INC
260 Sheridan Avenue, Suite 400
Palo Alto CALIFORNIA 94306 US
CEO: Ahmed M. Hamdy
Employees: 42
Phone: 16508006676
VINCERX PHARMA INC / VINC FAQ
What does VINC do?
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company which develops antibody drugs. The company is headquartered in Palo Alto, California and currently employs 12 full-time employees. The company went IPO on 2020-03-10. The firm is focused on developing differentiated and novel therapies to address the unmet medical needs of patients with cancer. The company has a next generation bioconjugation platform, called VersAptx. Its product candidates include VIP943 (CD123-KSPi), VIP924 (CXCR5-KSPi), VIP236, and Enitociclib (positive transcription elongation factor beta (P-TEFb)/CDK9 inhibitor). Its VIP943 is developed using its VersAptx platform and combines an anti-CD123 antibody, a novel legumain-cleavable linker and a kinesin spindle protein inhibitor payload enhanced with CellTrapper technology. Enitociclib is a selective CDK9 inhibitor. Enitociclib effectively blocks P-TEFb-mediated activation of RNA polymerase II, preventing transcription of MCL1 and MYC, proteins associated with poor prognosis in various types of cancer.
What is the current price of VINC stock?
The current stock price of VINC is 0.1 USD. The price decreased by -24.98% in the last trading session.
What is the dividend status of VINCERX PHARMA INC?
VINC does not pay a dividend.
What is the ChartMill rating of VINCERX PHARMA INC stock?
VINC has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does VINCERX PHARMA INC belong to?
VINCERX PHARMA INC (VINC) operates in the Health Care sector and the Biotechnology industry.
How many employees does VINCERX PHARMA INC have?
VINCERX PHARMA INC (VINC) currently has 42 employees.
When does VINCERX PHARMA INC (VINC) report earnings?
VINCERX PHARMA INC (VINC) will report earnings on 2025-05-12.